Drug Profile
Trastuzumab deruxtecan - AstraZeneca/Daiichi Sankyo
Alternative Names: DS 8201; DS 8201a; ENHERTU; Enhertu; fam-trastuzumab deruxtecan; fam-trastuzumab deruxtecan-nxki; T-DXd; VRN-101099Latest Information Update: 12 Feb 2024
Price :
$50
*
At a glance
- Originator Daiichi Sankyo Company
- Developer AstraZeneca; Bristol-Myers Squibb; Daiichi Sankyo Company; Fox Chase Cancer Center; Medica Scientia Innovation Research; National Comprehensive Cancer Network; Puma Biotechnology; Seagen
- Class Antineoplastics; Camptothecins; Drug conjugates; Immunoconjugates; Monoclonal antibodies
- Mechanism of Action DNA topoisomerase I inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Marketed Breast cancer; Gastric cancer; HER2 positive breast cancer; Non-small cell lung cancer
- Preregistration Solid tumours
- Phase II Adenocarcinoma; Biliary cancer; Colorectal cancer; Uterine cancer
- Phase I/II Urogenital cancer
Most Recent Events
- 06 Feb 2024 Daiichi Sankyo Company plans a phase I trial for Solid tumors (Late-stage-diseases, Metastatic-diseases, Combination therapy) (NCT06244485, DS3201-324)
- 29 Jan 2024 Preregistration for Solid tumours (Inoperable/Unresectable, Late-stage disease, Metastatic disease, Second-line therapy or greater) in USA (IV)
- 29 Jan 2024 FDA assigns PDUFA action date of 30/05/2024 for Trastuzumab deruxtecan for HER 2-positive solid tumors (Inoperable/Unresectable, Metastatic disease, Second-line therapy or greater) (IV)